Todd Graves

TL;DR: Among patients with acute stroke who had last been known to be well 6 to 24 hours earlier and who had a mismatch between clinical deficit and infarct, outcomes for disability at 90 days were better with thrombectomy plus standard care than with standard care alone.

TL;DR: To establish whether subjects considered to have substantial areas of salvageable brain based on age-adjusted clinical core mismatch who can undergo endovascular treatment within 6–24 h from time last seen well (TLSW) have better outcomes at three months compared to subjects treated with standard medical therapy alone.

TL;DR: A utility-weighted mRS performs similar to the standard ordinal mRS in detecting treatment effects in actual stroke trials and ensures the quantitative outcome is a valid reflection of patient-centered benefits.

TL;DR: Among patients with septic shock receiving norepinephrine, administration of selepressin, compared with placebo, did not result in improvement in vasopressor- and ventilator-free days within 30 days.

TL;DR: SEPSIS-ACT is an innovative trial evaluating selepressin, a novel selective vasopressin V1a receptor agonist, for adults with septic shock, that addresses both optimal dose and confirmation of benefit, accelerating the evaluation of sele pressin while mitigating risks to patients and sponsor through use of response-adaptive randomization, a Novel registration endpoint, prespecified futility stopping rules, and a large sample size.